{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2531","pValueComment":"Two-sided significance level = 0.05","statisticalComment":"Welch t-test (unequal variances)","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-9.62","upperLimit":"2.80","value":"-3.41"},{"groupId":"OG001","lowerLimit":"-16.11","upperLimit":"-1.54","value":"-8.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"The PSS HN Understandability of Speech score measures clinician rated speech. Possible scores range from 0 to 100, with higher scores indicating better speech function. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate worsening function.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMRT for seven weeks, 5 fractions/week. Cetuximab 400 mg/m\\^2 IV starts one week prior to RT, then 250 mg/m\\^2 weekly for seven additional cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"RT + Cetuximab"},{"description":"IMRT for seven weeks, 5 fractions/week. Durvalumab 1500 mg IV starts two weeks prior to RT and continues every 4 weeks for a total of seven cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"RT + Durvalumab"}],"paramType":"MEAN","populationDescription":"Randomized participants with baseline and one-year data.","reportingStatus":"POSTED","timeFrame":"Baseline and one year after end of radiation therapy (approximately 7 weeks)","title":"Change in PSS HN Understandability of Speech Score at One Year","type":"SECONDARY","unitOfMeasure":"score on a scale"}